Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.64 |
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | CTSK | P43235 | 4/20 | 0.61 |
| ▸ | CTSS | P25774 | 3/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763894 | 1.00 | JAK3 (0.64) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL3720453 | 1.00 | JAK3 (0.64) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL20374864 | 0.94 | JAK3 (0.61) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL5806085 | 0.93 | JAK3 (0.68) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL3718681 | 0.93 | JAK3 (0.68) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL18409020 | 0.89 | JAK3 (0.55) | JAK3BTKCTSKCTSSPPARA | |
| SCHEMBL7035410 | 0.89 | JAK3 (0.54) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL6163545 | 0.89 | CTSK (0.65) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL6163542 | 0.89 | CTSK (0.65) | JAK3BTKCTSKCTSSCTSL | |
| SCHEMBL1204211 | 0.88 | JAK3 (0.61) | JAK3BTKCTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002048097-A9 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INT INC (US) | 2003-05-08 | — | — | WO | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | DENDREON CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2002048097-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INTERNATIONAL, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | CAT, CTSA, CTRL | JAK3 3877/4885BTK 3325/4885CTSK 17/4885 |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | JAK3 2527/4885BTK 2080/4885CTSK 29/4885 |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | JAK3 2680/4885BTK 2525/4885CTSK 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.